Jiuzhou Pharmaceutical announced that its holding subsidiary Zhejiang Jiuzhou Biomedical Co., Ltd. received the “Drug Registration Certificate” for sildenafil citrate tablets approved and issued by the State Drug Administration. The drug is an iterative dosage form of sildenafil developed by Pfizer with a focus on patients, and was approved for import in China in 2019. Currently, the main domestic manufacturers that have obtained this drug registration certificate include Sichuan Colun Pharmaceutical and Guangdong Taienkang Pharmaceutical. The total sales volume of sildenafil citrate tablets in the domestic medical market and retail market in 2023 was RMB 5.217 billion. Jiuzhou Pharmaceutical has invested a total of 13.52 million yuan in R&D of sildenafil citrate tablets.

Zhitongcaijing · 07/01/2025 07:49
Jiuzhou Pharmaceutical announced that its holding subsidiary Zhejiang Jiuzhou Biomedical Co., Ltd. received the “Drug Registration Certificate” for sildenafil citrate tablets approved and issued by the State Drug Administration. The drug is an iterative dosage form of sildenafil developed by Pfizer with a focus on patients, and was approved for import in China in 2019. Currently, the main domestic manufacturers that have obtained this drug registration certificate include Sichuan Colun Pharmaceutical and Guangdong Taienkang Pharmaceutical. The total sales volume of sildenafil citrate tablets in the domestic medical market and retail market in 2023 was RMB 5.217 billion. Jiuzhou Pharmaceutical has invested a total of 13.52 million yuan in R&D of sildenafil citrate tablets.